Mylan Specialty LP
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1978-01-01
- Employees
- 501
- Market Cap
- -
Clinical Trials
2
Active:0
Completed:1
Trial Phases
1 Phases
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (100.0%)Study of MR-107A-02 in the Treatment of Post Surgical Dental Pain.
Phase 2
Completed
- Conditions
- Post Operative PainAcute PainPain
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-04-07
- Last Posted Date
- 2023-08-07
- Lead Sponsor
- Mylan Specialty, LP
- Target Recruit Count
- 111
- Registration Number
- NCT05317312
- Locations
- 🇺🇸
Research Facility 201, Salt Lake City, Utah, United States
Intravenous Milk Thistle (Silibinin-Legalon) for Hepatic Failure Induced by Amatoxin/Amanita Mushroom Poisoning
Phase 2
Terminated
- Conditions
- Amanita PoisoningMushroom PoisoningAmatoxin PoisoningLiver Failure
- Interventions
- First Posted Date
- 2009-06-08
- Last Posted Date
- 2022-04-07
- Lead Sponsor
- Mylan Specialty, LP
- Target Recruit Count
- 148
- Registration Number
- NCT00915681
- Locations
- 🇺🇸
Recruitment Hot Line for the United States, Somerset, New Jersey, United States
🇺🇸Mylan Specialty LLP, Morgantown, West Virginia, United States
News
No news found